Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
Ada KoschorkeSimona FaraciDebora GianiClaudia ChiodoniEgidio IorioRossella CaneseMario P ColomboAlessia LamolinaraManuela IezziMichael LadomeryClaudio VernieriFilippo de BraudMassimo Di NicolaElda TagliabueLorenzo CastagnoliSerenella Maria PupaPublished in: Cellular oncology (Dordrecht) (2019)
Our results indicate that PEITC targets HER2-positive CSCs and that its combination with trastuzumab may pave the way for a novel therapeutic strategy for HER2-positive tumors.